US-based 4D Molecular Therapeutics (4DMT) has entered into a collaboration and license agreement with Roche for the discovery and development of optimized next-generation adeno-associated virus (AAV) vectors for indications with high unmet medical need.
Under the deal, 4DMT will deploy its AAV vector discovery platform, Directed Vector Evolution, to discover and optimize new gene delivery vectors for use in gene therapy products.
Commenting on this collaboration with Roche, 4DMT co-founder and CEO Dr David Kirn said: "We believe that great synergies can be achieved by combining our AAV gene therapy platform discovery with Roche’s expertise in novel biologics.
"Together we can potentially develop transformative new gene therapies. As the fourth collaboration to be announced by 4D over the last year, we are realizing our vision of creating a robust product pipeline with our partners."
The deal was facilitated by QB3, a multi-campus University of California, including UC Berkeley & UC San Francisco, research institute and biotech accelerator.